S. S. Bielack, S. Smeland, J. Whelan, et al., “MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 “good response” randomization,” Journal of Clinical Oncology, vol. 31, Article ID LBA10504, 2013.
[2]
A.-M. Cleton-Jansen, J. K. Anninga, I. H. Briaire-De Bruijn et al., “Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways,” British Journal of Cancer, vol. 101, no. 11, pp. 1909–1918, 2009.
[3]
S. P. Chawla, A. P. Staddon, L. H. Baker et al., “Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas,” Journal of Clinical Oncology, vol. 30, no. 1, pp. 78–84, 2012.
[4]
G. D. Demetri, S. P. Chawla, I. Ray-Coquard, et al., “Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus to control metastatic sarcoma in patients after benefit from prior chemotherapy,” Journal of Clinical Oncology, vol. 31, no. 19, pp. 2485–2492, 2013.